Takeda Pharmaceutical (TAK) Gross Margin (2017 - 2026)

Takeda Pharmaceutical's Gross Margin history runs 10 years deep, the most recent figure standing at 62.93% for Q1 2026.

• In Q1 2026, Gross Margin fell 502.0% year-over-year to 62.93%; the TTM figure through Mar 2026 stood at 65.16% (down 62.0% YoY), while the FY2026 annual figure was 65.12%, up 4720.0% from the prior year.
• Gross Margin was 62.93% for Q1 2026 at Takeda Pharmaceutical, roughly flat from 62.89% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 216.46% in Q3 2022 to a low of 59.22% in Q4 2022.
• Historically, Gross Margin has averaged 74.82% across 5 years, with a median of 66.03% in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 14911 bps in 2022, then sank 14749 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 59.22% in 2022, then grew by 7 bps to 63.64% in 2023, then declined by 0 bps to 63.59% in 2024, then retreated by 1 bps to 62.89% in 2025, then rose by 0 bps to 62.93% in 2026.
• The last three Gross Margin figures came in at 62.93% (Q1 2026), 62.89% (Q4 2025), and 66.03% (Q3 2025), per Business Quant data.